Matt Galsky, MD, discusses the phase 3 NIAGARA trial that led to the recent FDA approval of durvalumab in muscle-invasive ...

Matt Galsky, MD, delved into the recent approval of a perioperative durvalumab regimen in muscle-invasive bladder cancer.

An exploratory analysis shows a reduction in extrathoracic metastases and prolonged time to progression or death due to any metastases with durvalumab vs placebo.

EU approves AstraZeneca’s Imfinzi-in combo with chemotherapy to treat patients with resectable non-small cell lung cancer ...

Approval was based on improved survival outcomes vs platinum-based chemotherapy as demonstrated in the phase 3 NIAGARA study.

The approval follows the December 2024 priority review designation for this perioperative immunotherapy regimen for patients fighting muscle-invasive bladder cancer (MIBC).

neoadjuvant chemotherapy alone WILMINGTON, Del., March 31, 2025--(BUSINESS WIRE)--AstraZeneca’s IMFINZI ® (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment ...

The FDA has approved Imfinzi® (durvalumab), in combination with gemcitabine and cisplatin, for the treatment of adult patients with MIBC.

The FDA has approved neoadjuvant durvalumab plus chemotherapy followed by adjuvant durvalumab after radical cystectomy in MIBC.

The FDA approved several therapies in oncology in the month of March 2025. These drugs included treatments for ...

UK pharma major AstraZeneca (LSE: AZN) today reported extended approvals in Europe for two of its cancer drugs: Imfinzi ...